VRTX
Vertex Pharmaceuticals Incorporated
Balance sheet
| USDLine, in USD | Q3 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.3B | 6.6B | 6.1B | 11.2B | 10.8B | 7.5B | 6.7B | 3.8B | 3.2B | 2.1B | 1.4B | 1.0B | 1.4B | 1.5B | 1.3B | 969M | 1.0B | 1.3B | — | |
Inventory | 2.25B | 1.69B | 1.21B | 0.74B | 0.46B | 0.35B | 0.28B | 0.17B | 0.12B | 0.11B | 78M | 57M | 31M | 14M | 30M | 0.11B | — | — | — |
| Current assets | 11.7B | 11.2B | 9.6B | 14.1B | 13.2B | 9.6B | 8.1B | 4.8B | 3.8B | 2.6B | 1.8B | 1.4B | 1.5B | 1.6B | 1.6B | 1.3B | 1.1B | 1.3B | — |
Goodwill | 2.42B | 1.09B | 1.09B | 1.09B | 1.09B | 1.00B | 1.00B | 1.00B | 50M | 50M | 50M | 50M | 40M | 31M | 31M | 31M | 26M | 26M | — |
Intangible assets | 8.52B | 0.42B | 0.83B | 0.84B | 0.60B | 0.40B | 0.40B | 0.40B | 0 | — | — | — | — | — | — | — | — | — | — |
| Total assets | 32.7B | 25.6B | 22.5B | 22.7B | 18.2B | 13.4B | 11.8B | 8.3B | 6.3B | 3.6B | 2.9B | 2.5B | 2.3B | 2.3B | 2.8B | 2.2B | 1.7B | 2.0B | — |
Current liabilities | 5.00B | 3.86B | 3.56B | 3.55B | 2.74B | 2.14B | 1.88B | 1.33B | 1.12B | 0.81B | 0.79B | 0.51B | 0.37B | 0.40B | 0.43B | 0.39B | 0.47B | 0.28B | — |
| 3.50B | 0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Total liabilities | 11.8B | 7.0B | 6.1B | 5.1B | 4.2B | 3.3B | 3.1B | 2.2B | 1.8B | 1.5B | 1.6B | 1.4B | 1.2B | 963M | 1.5B | 1.2B | 1.2B | 859M | — |
| Shareholders' equity | 20.9B | 18.7B | 16.4B | 17.6B | 13.9B | 10.1B | 8.7B | 6.1B | 4.4B | 2.0B | 1.2B | 940M | 1.1B | 1.4B | 999M | 787M | 504M | 1.1B | 239M |
| Shares outstanding | 253.5M | 254.0M | 256.8M | 258.3M | 257.1M | 254.6M | 260.0M | 259.3M | 255.7M | 253.9M | 248.4M | 246.4M | 242.1M | 235.8M | 218.2M | 210.3M | 204.4M | — | — |
| Current ratio | 2.34 | 2.90 | 2.69 | 3.99 | 4.83 | 4.46 | 4.33 | 3.61 | 3.43 | 3.28 | 2.31 | 2.78 | 4.20 | 3.99 | 3.67 | 3.39 | 2.23 | 4.59 | — |